Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06025630 · ClinicalTrials.gov registry record · Phase 1
Targeting Endoplasmic Reticulum Stress in Human Hypertension
A Phase 1 study of Hypertension, sponsored by University of North Texas Health Science Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06025630: Recruiting Phase 1 study of Hypertension, sponsored by University of North Texas Health Science Center.
NCT06025630 is a Phase 1 study of Hypertension that is actively recruiting participants, run by University of North Texas Health Science Center. The registered enrollment target is 70 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06025630, a Phase 1 study of Hypertension, is actively recruiting participants, sponsored by University of North Texas Health Science Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.
Primary Outcome
Systolic and diastolic blood pressure will be measured twice per hour during the day and once per hour at night using a portable cuff.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TUDCA
Study Locations (1)
Texas
- University of North Texas Health Science Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT06025630 shows while recruiting
NCT06025630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06025630 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06025630 about?
NCT06025630 is a clinical study titled "Targeting Endoplasmic Reticulum Stress in Human Hypertension". There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in hum...
What is the current status of trial NCT06025630?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2023-08-15. Estimated completion is 2028-12-31.
What conditions does trial NCT06025630 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT06025630?
The interventions under investigation include: Placebo (DRUG), TUDCA (DRUG).
Who is sponsoring clinical trial NCT06025630?
This trial is sponsored by University of North Texas Health Science Center, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06025630 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06025630's enrollment target sits among peer trials
70 334th of 470 higher than 133 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI